RE: US needs more antivirals for covid3 Jun 2022 12:35
What we're watching: "There's so many different promising drugs that aren't being pursued, or they're being pursued by small companies" that don't have adequate support, said Eric Topol, executive vice president of Scripps Research.
A major upside of these products are that they're variant-proof, Topol said, which means they'll continue to work against the virus as it evolves